Asenapine (Saphris®)
Asenapine (US brand name Saphris®) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Schizophrenia 2. Acute treatment of manic and mixed episodes associated with bipolar I disorder (monotherapy) 3. Acute treatment of manic and mixed episodes associated with bipolar I disorder (adjunctive to lithium or valproate) […]
Read More